Nicolucci, Antonio <br/><br/>
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.  [electronic resource] 

 -  Advances in therapy  10 2019 
 - 2895-2909 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1865-8652 
<br/><br/><label>Standard No.: </label>10.1007/s12325-019-01043-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Benzhydryl Compounds--adverse effects<br/>Canagliflozin--adverse effects<br/>Cardiovascular Diseases--chemically induced<br/>Cross-Sectional Studies<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Female<br/>Glucosides--adverse effects<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Male<br/>Middle Aged<br/>Sodium-Glucose Transporter 2--drug effects<br/>Sodium-Glucose Transporter 2 Inhibitors--adverse effects<br/>United States